Since October 2017, Mr. Scodari has served as Chairman of the Board of Directors of Optinose (NASDQ:OPTN), a specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (“ENT”) and allergy specialists. Mr. Scodari was previously Worldwide Chairman, Pharmaceuticals Group, of Johnson & Johnson, and a member of Johnson & Johnson’s Executive Committee from March 2005 until his retirement in March 2008. From 2003 to March 2005, Mr. Scodari was Company Group Chairman of Johnson & Johnson’s Biopharmaceutical Business. Mr. Scodari joined Centocor in 1996 as President, Pharmaceutical Division and was named President and COO in 1998, a position that he served in until Centocor Inc.’s acquisition by Johnson & Johnson in 1999. Mr. Scodari began his career in 1974 in sales for Winthrop Laboratories, Division of Sterling Drug.
He progressed through various management positions, eventually leading the Diagnostic Imaging Division for Winthrop and later Strategic Marketing at the Corporate level for the Imaging business. Mr. Scodari joined Rorer Pharmaceuticals (shortly thereafter, Rhône-Poulenc Rorer) in 1989 as Vice President of Marketing and Business Development. He later served as Vice President and General Manager for the United States, and subsequently, North America, and finally as Senior Vice President and General Manager for the Americas. Mr. Scodari previously served as a director of Actelion Pharmaceuticals, Ltd., Endo Health Solutions, Inc. and Covance, Inc. Mr. Scodari has served on various non-profit boards, including the University of the Health Sciences in Philadelphia, the Board of Overseers for the Robert Wood Johnson School of Medicine, and on the Board of Trustees for Gwynedd Mercy College. He has also served on various industry association boards, including the NWDA Associate Member Board, the National Pharmaceutical Council, as Vice Chairman of the Biotechnology Industry Organization (“BIO”), and Chairman of PA BIO. Mr. Scodari received a B.A. from Youngstown State University. Mr. Scodari was selected to serve on our board of directors because of his extensive experience in the pharmaceutical industry.
What is Joseph C. Scodari's net worth?
The estimated net worth of Joseph C. Scodari is at least $1.80 thousand as of January 6th, 2025. Scodari owns 1,385 shares of Acurx Pharmaceuticals stock worth more than $1,801 as of October 7th. This net worth evaluation does not reflect any other assets that Scodari may own. Learn More about Joseph C. Scodari's net worth.
How do I contact Joseph C. Scodari?
Has Joseph C. Scodari been buying or selling shares of Acurx Pharmaceuticals?
Joseph C. Scodari has not been actively trading shares of Acurx Pharmaceuticals during the past quarter. Most recently, on Monday, January 6th, Joseph C. Scodari bought 1,231 shares of Acurx Pharmaceuticals stock. The stock was acquired at an average cost of $20.20 per share, with a total value of $24,866.20. Following the completion of the transaction, the director now directly owns 1,385 shares of the company's stock, valued at $27,977. Learn More on Joseph C. Scodari's trading history.
Who are Acurx Pharmaceuticals' active insiders?